lorcaserin and Renal-Insufficiency

lorcaserin has been researched along with Renal-Insufficiency* in 1 studies

Trials

1 trial(s) available for lorcaserin and Renal-Insufficiency

ArticleYear
Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.
    Clinical therapeutics, 2017, Volume: 39, Issue:4

    To determine whether dosage adjustment is likely to be necessary for effective and well-tolerated use of a pharmaceutical agent, guidance documents from the US Food and Drug Administration recommend pharmacokinetics studies in patients with impaired renal or impaired hepatic function and in the elderly population. Three studies were conducted to evaluate the pharmacokinetic properties and tolerability of lorcaserin in these populations.. Lorcaserin was evaluated in single-dose pharmacokinetics studies of 3 overweight/obese populations: (1) elderly (aged >65 years) patients; (2) patients with impaired renal function; and (3) those with impaired hepatic function.. In elderly patients, C. Based on these findings, no lorcaserin dose adjustments are necessary in elderly patients with normal renal function or in patients with mild/moderate renal or hepatic impairment. ClinicalTrials.gov identifiers: NCT00828581, NCT00828438, and NCT00828932.

    Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Area Under Curve; Benzazepines; Dose-Response Relationship, Drug; Female; Humans; Liver Diseases; Male; Middle Aged; Renal Insufficiency; Young Adult

2017